Key result
Rivaroxaban linked to ~0.45 strokes per 100 patient-years and low bleeding rates in nonvalvular AF.
Why the study?
What are the real-world thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban?
Cohort
No
What are the real-world thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban?
In a real-world regional hospital setting, rivaroxaban treatment for nonvalvular atrial fibrillation demonstrated low rates of discontinuation, thromboembolic events, and bleeding.
Supports low event rates with rivaroxaban in real-world NVAF; hypothesis-generating and requires prospective validation before practice change.
AIM: To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital. METHODS: Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital. RESULTS: -VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74.1% of patients. Among patients treated with rivaroxaban 20 and 15 mg, only 3.6 and 22.5%, respectively, received an inadequate dose. After 26.6 ± 11.6 months of treatment, annual discontinuation rate was 1%. Rates of stroke, major bleeding and intracranial hemorrhage were 0.45, 0.22 and 0.22 events/100 patient years, respectively. CONCLUSION: In our practice of regional hospital, rates of discontinuation, thromboembolic and bleeding outcomes are low.
No takes yet. Share an insight, caveat, or question.
Lobato et al. (2018) conducted a cohort in nonvalvular atrial fibrillation. Rivaroxaban was evaluated on stroke, major bleeding and intracranial hemorrhage. Rivaroxaban treatment in patients with nonvalvular atrial fibrillation was associated with low rates of stroke (0.45), major bleeding (0.22), and intracranial hemorrhage (0.22 events/100 pt-years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: